Carregant...
Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments
BACKGROUND: Galcanezumab is a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) indicated for the preventive treatment of migraine. While galcanezumab has demonstrated efficacy in patients who did not respond to prior preventive medications in general, its efficacy in patients who did...
Guardat en:
| Publicat a: | BMC Neurol |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8063415/ https://ncbi.nlm.nih.gov/pubmed/33892641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-021-02196-7 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|